Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04852757
Other study ID # PsyCOVIDUM
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 25, 2021
Est. completion date April 30, 2023

Study information

Verified date September 2023
Source Fondation Hôpital Saint-Joseph
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In December 2019, infection with a new coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in China and has since spread throughout the world. Forms of varying severity of COVID-19, a disease induced by this emerging virus, have been described in pregnant women. In addition to the direct effects of the virus on the pregnant woman and the fetus, the pandemic context itself is likely to act as a psychological risk factor and to alter the protective factors for mental disorders. This pandemic context is in itself anxiety-provoking, even traumatogenic, particularly because of the potentially lethal infectious risk that it conveys, all the more so in psychologically vulnerable populations. In addition to the fear of viral contamination, the fear of childbirth and the postpartum period, which includes a more or less important part of anxiety-provoking uncertainty, is added to the fear of viral contamination in the perinatal period. This addition of stress factors is likely to increase the prevalence of perinatal depressive disorders and anxiety disorders, particularly the psychotraumatic experience of childbirth. Sanitary and social measures, such as quarantine, restriction of access of accompanying persons to maternity unit, or contagious isolation of mothers suspected of being infected or infected, which may furthermore impose a separation of mother and child, are also likely to have psychopathological consequences. In this context, three maternity wards of the PREMA University Hospital Federation (UHF PREMA) : Groupe hospitalier Paris Saint-Joseph (GHPSJ), Louis Mourier Hospital (APHP) and Port-Royal Hospital (APHP), in partnership with the "Centre de Psychopathologie du Boulevard Brune (CPBB)" and the psychiatry department of the Louis Mourier Hospital have set up a care protocol consisting of a systematic screening offered to women following childbirth on the first day of their pregnancy, aimed at identifying those with perinatal anxiety and depressive symptoms. Women presenting symptoms are then treated according to the modalities adapted to the organization of each of these three centers.


Description:

Screening in these three centers is based on the use of a self-administered questionnaire for the detection of depressive disorders, the Edinburgh Postnatal Depression Scale (EPDS), which allows the calculation of a score. In addition to the EPDS, three other tools are used at the GHPSJ maternity : a questionnaire to screen for anxiety, the State-Trait Anxiety Inventory (STAI-S), and two for trauma symptoms, the Peritraumatic Dissociative Experiences Questionnaire (PDEQ) and the Peritraumatic Distress Inventory (PDI). In this center, the screening includes a second phase with a home mailing between 6 and 8 weeks after delivery: the EPDS, the STAI-S and the Impact Events Scale-Revised (IES-R), another test screening for post-traumatic stress. Based on the protocol implemented in these three maternity hospitals, the present research project aims to estimate the prevalence of postpartum depressive disorders at different times during and after the COVID-19 pandemic. It will also aim to identify the factors associated with the occurrence of these disorders, primarily to determine the association between elements of the pandemic context and the risk of postpartum depressive and anxiety disorders. This project, which is based on an epidemiological approach, thus aims to assess the mental health risks associated with the COVID-19 pandemic. Postpartum women are a particularly vulnerable group, especially in terms of mental health. Indeed, 1 to 5% develop post-traumatic stress disorder during this period and 10 to 20% develop post-partum depression. Furthermore, the National Confidential Survey on Maternal Deaths (NCSMD) shows that suicide is now the leading cause of maternal death in France (i.e., death occurring between conception and the first year following birth), before postpartum hemorrhage and before preeclampsia (data not yet published). From pooled English, Dutch, and French data, we observe that 36% of maternal deaths occurring between conception and the first year postpartum are deaths by suicide. The COVID-19 pandemic and the associated measures that went as far as confining the population were very likely to increase the factors favouring the occurrence of mental health impairment in the general population, but perhaps even more so in certain at-risk groups such as postpartum women. The pandemic context, whether through the fears associated with the viral infection for oneself or one's family, or through the consequences of the exceptional measures put in place in many countries to limit viral circulation, has had an effect on the general population and on the population of women in pregnancy, in different contexts. To date and to our knowledge, there is no data that would allow us to know the impact that this context may have had on the mental health of pregnant women in France. Moreover, there are no studies, either in France or elsewhere, on the impact of this pandemic context on the prevalence of psychological disorders in the postpartum period. However, this period is already a time of particular psychological vulnerability, a time when the risk of maternal suicide is at its highest. It is moreover reasonable to think that the pandemic impact and the general and local measures that accompany it may have an even greater impact during this postpartum period. The measures taken to prevent and protect against viral dissemination have had the effect of completely closing most maternity services to fathers and thus depriving mothers, totally or partially, of social and marital support and, in some situations, of physical proximity to their children, all of which are risk factors for postpartum depression. In the perinatal context, it has also been documented that post-traumatic stress disorder is strongly associated with the risk of perinatal depression.


Recruitment information / eligibility

Status Completed
Enrollment 2580
Est. completion date April 30, 2023
Est. primary completion date October 31, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult pregnant women delivering after 24 weeks of amenorrhea between April 6, 2020 and the end of the COVID-19 epidemic in one of the three participating maternity units - French speaking patient Exclusion Criteria: - Situation of fetal death or Medical Interruption of Pregnancy - Patient under guardianship or curators - Patient deprived of liberty - Patient under court protection - Patient opposing the use of his data for this research.

Study Design


Locations

Country Name City State
France Groupe Hospitalier Paris Saint Joseph Paris Ile-de-France

Sponsors (1)

Lead Sponsor Collaborator
Fondation Hôpital Saint-Joseph

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Follow the evolution of the prevalence of women in immediate postpartum presenting a depressive and/or anxious symptomatology in the population of 3 maternity units in the Paris area Evolution during pandemic fluctuations of the proportion of women with a positive screen for anxiety and/or depressive disorders in the immediate postpartum 2 months
Secondary Estimate the prevalence, in the context of a COVID-19 pandemic, of women in the immediate postpartum period presenting depressive and/or anxious symptoms (EPDS) in the population of women giving birth (in the 3 hospitals) Prevalence of women with immediate postpartum EPDS >10. Day 3
Secondary Estimate, in the context of a COVID-19 pandemic, the prevalence of women in the immediate postpartum period presenting depressive and/or anxious symptoms (STAI-S) in the population of women giving birth (in the 3 hospitals) Prevalence of women with immediate postpartum (STAI-S) > 45 Day 3
Secondary Estimate, in the context of a COVID-19 pandemic, the prevalence of women in the immediate postpartum period presenting depressive and/or anxious symptoms (PDEQ) in the population of women giving birth (in the 3 hospitals) Prevalence of women with immediate postpartum Peritraumatic Dissociative Experiences Questionnaire (PDEQ) > 15 Day 3
Secondary Estimate, in the context of a COVID-19 pandemic, the prevalence of women in the immediate postpartum period presenting depressive and/or anxious symptoms (PDI) in the population of women giving birth (in the 3 hospitals) Prevalence of women with immediate postpartum Peritraumatic Distress Inventory scale (PDI) > 15 Day 3
Secondary Estimate in the context of a COVID-19 pandemic the prevalence of women at 2 months postpartum with depressive and/or anxious symptoms (EPDS) in the population of women giving birth at the GhPSJ maternity hospital Prevalence of women with immediate postpartum EPDS >10 2 months
Secondary Estimate in the context of a COVID-19 pandemic the prevalence of women at 2 months postpartum with depressive and/or anxious symptoms (STAI-S) in the population of women giving birth at the GhPSJ maternity hospital Prevalence of women with immediate postpartum (STAI-S) > 45 2 months
Secondary Estimate in the context of a COVID-19 pandemic the prevalence of women at 2 months postpartum with depressive and/or anxious symptoms (PDEQ) in the population of women giving birth at the GhPSJ maternity hospital Prevalence of women with immediate postpartum Peritraumatic Dissociative Experiences Questionnaire (PDEQ) > 15 2 months
Secondary Estimate in the context of a COVID-19 pandemic the prevalence of women at 2 months postpartum with depressive and/or anxious symptoms (IES-R) in the population of women giving birth at the GhPSJ maternity hospital Prevalence of women with immediate postpartum Impact Events Scale-Revised (IES-R) > 12 2 months
Secondary Investigate factors associated with the risk of developing depressive and/or anxiety symptomatology in the COVID-19 pandemic context Measure of association between COVID-19 infection and risk of having a score above the cutoff 3 days to 2 months
Secondary Investigate factors associated with the risk of developing depressive and/or anxiety symptomatology in the COVID-19 pandemic context Measure of association between time of delivery (reflecting exposure to general and local quarantine, as well as risk of viral infection) and risk of having a score above the cutoff 3 days to 2 months
Secondary Investigate factors associated with the risk of developing depressive and/or anxiety symptomatology in the COVID-19 pandemic context Measure of association between maternal socio-familial isolation in the postpartum period and the risk of having a score above the cutoff 3 days to 2 months
Secondary Investigate factors associated with the risk of developing depressive and/or anxiety symptomatology in the COVID-19 pandemic context Measure of association between mother-child separation in the postpartum period and risk of having a score above the cutoff 3 days to 2 months
Secondary Comparison of the prevalence of anxiety and depressive disorders among women not infected with SARS-CoV2 in PsyCOVIDUM with those infected in the COROPREG study (COVID-19 and pregnancy: a population-based cohort of women and newborns) Measuring the impact of maternal COVID-19 infection on anxiety-depressive symptomatology. 2 months
See also
  Status Clinical Trial Phase
Completed NCT04012580 - Examining the Effectiveness of Transdiagnostic, Internet-Delivered Cognitive Behaviour Therapy in New Mothers Experiencing Anxiety and Depression N/A
Recruiting NCT05813782 - The Effect of Baby Massage on Postpartum Depression and Maternal Attachment N/A
Recruiting NCT05907213 - Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery Phase 1
Completed NCT00602732 - Interpersonal Treatment Program to Prevent Depression and Post-Traumatic Stress Disorder in Low-Income Pregnant Women With Partner Abuse Phase 1
Completed NCT00053651 - Prevention of Postpartum Depression in Low-Income Women Phase 1
Completed NCT00043602 - Clinician Managed Interpersonal Psychotherapy Phase 0
Completed NCT04169334 - Look - Your Baby is Talking to You. N/A
Completed NCT03573713 - Decreasing Stunting by Reducing Maternal Depression in Uganda: A Cluster Randomized Controlled Trial (CRCT) for Improved Nutrition Outcomes N/A
Completed NCT04043533 - The Effect of an Exercise Program in Reducing the Severity of Postpartum Depression in Women N/A
Completed NCT06070168 - Determining the Effect of Telephone Counseling Service Provided to Primiparous Mothers on Postpartum Depression N/A
Recruiting NCT05050266 - Enhancing Mental and Physical Health of Women Veterans N/A
Completed NCT02505984 - Preventing Postpartum Depression With Intranasal Oxytocin Phase 2
Recruiting NCT00251342 - Outcome of Postnatal Depression Screening Using Edinburgh Postnatal Depression Scale Phase 2/Phase 3
Completed NCT02526407 - The Impact of Creative Interventions on Symptoms of Postnatal Depression N/A
Completed NCT02526433 - The Impact of Creative Interventions on Symptoms of Postnatal Depression (Cohort Study) N/A
Completed NCT03574766 - Meditation for NICU Moms N/A
Completed NCT03646539 - RCT of Automated Conversational Agent vs. Treatment as Usual for the Management of Perinatal Mood N/A
Active, not recruiting NCT05110456 - To Evaluate the Effectiveness of a Virtual and Telephone Intervention for the Prevention of Postpartum Depression in Women at Risk N/A
Recruiting NCT04154423 - Engaging Mothers & Babies; Reimagining Antenatal Care for Everyone (EMBRACE) Study N/A
Not yet recruiting NCT04093791 - MAMA NO STRESS Project. The Effects of the "HAPPY MAMA" Intervention N/A